STAT+: FDA’s new guidance on AI in drug development centers the risk introduced by the technology
STAT
JANUARY 6, 2025
After nearly a decade of machine learning innovation in the drug industry, the Food and Drug Administration Monday published its first draft guidance on the use of artificial intelligence in the development of drugs and biological products. The guidance comes as drug regulatory submissions citing AI have increased exponentially. In an interview with STAT in October, the FDA’s Tala Fakhouri, who co-leads the Center for Drug Evaluation and Research’s AI Council, said the agency has r
Let's personalize your content